Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
Proteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment
A webinar presented by Clare Paterson, PhD, Associate Director of Clinical Research, SomaLogic, and Jessica Chadwick, PhD, Scientist, SomaLogic
Abstract
In this 1-hour discussion, you will learn how large-scale proteomics can be leveraged for multiple applications in the field of oncology. The focus will be on two new avenues of oncology research. The first is using proteomic risk scores to monitor the cardiotoxic effects of anthracycline treatment and identify patients who may benefit from cardioprotective therapy. The other is developing blood-based protein tests for stratifying lung cancer susceptibility. From biomarker discovery to medicine application and the potential to inform and impact patients’ standard of care—there is a lot to learn and look forward to in oncology research using proteomics.
Clare Paterson, PhD
Associate Director of Clinical Research, SomaLogic
Prior to SomaLogic, Dr. Paterson conducted a fellowship in the clinical brain disorders branch at the National Institutes of Health (NIH) before becoming an Assistant Professor in Psychiatry at the University of Colorado School of Medicine.
Her academic research career focused on the use of -omics technologies to map how the human brain develops and ages and is altered in psychiatric illnesses, with the aim of ultimately uncovering new means of patient stratification and treatment discovery.
Jessica Chadwick, PhD
Scientist, SomaLogic
Dr. Jessica Chadwick is a scientist in the Clinical Research & Development department at SomaLogic. She completed her PhD in biochemistry at The Ohio State University as an NIH fellow. Her academic research focused on novel therapeutic strategies for treating Duchenne muscular dystrophy.
Dr. Chadwick has worked at SomaLogic for over 5 years on the development and productization of proteomic-based cardiometabolic tests. More recently she led an exciting new body of work aimed at assessing the robustness and sensitivity of these tests to interventions.
Protein biomarker models for oncology risk assessment and treatment monitoring
A webinar presented by Clare Paterson, MD, and Jessica Chadwick, MD
Contact us to learn more today
More webinars
WebinarIdentifying Biomarkers for IBD Diagnosis and Management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
WebinarBoutique Webinar : Predicting Pregnancy Complications with High-Plex Proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth.
WebinarYoung blood for old brains and the quest to slow brain aging
Aging leads to the degradation of function in nearly all tissues and organs. This process is marked by significant shifts in gene expression and changes in concentrations of all types of biological molecules. Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism